Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Abivax
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
August 06, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Provides Operational and Key Program Update
July 15, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
June 04, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
May 08, 2024
From
Abivax
Via
GlobeNewswire
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
May 07, 2024
From
Abivax
Via
GlobeNewswire
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
April 05, 2024
From
Abivax
Via
GlobeNewswire
Abivax reports 2023 financial results and operational update
April 02, 2024
From
Abivax
Via
GlobeNewswire
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
February 07, 2024
From
Abivax
Via
GlobeNewswire
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
February 02, 2024
From
Abivax
Via
GlobeNewswire
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
January 24, 2024
From
Abivax
Via
GlobeNewswire
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
January 22, 2024
From
Abivax
Via
GlobeNewswire
Abivax 2024 Financial Communication Calendar
January 04, 2024
From
Abivax
Via
GlobeNewswire
Abivax announces the resumption of its liquidity contract
November 21, 2023
From
Abivax
Via
GlobeNewswire
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
From
Abivax
Via
GlobeNewswire
Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting
June 10, 2022
From
ABIVAX
Via
AccessWire
Abivax Phase 2a Study Results of Obefazimod (ABX464) in Rheumatoid Arthritis Published in the Journal "Annals of the Rheumatic Diseases" and Selected for Presentation at EULAR 2022
June 01, 2022
From
ABIVAX
Via
AccessWire
Abivax Announces Annual Ordinary and Extraordinary General Meeting on June 9, 2022, and the Availability of the Preparatory Documents
May 18, 2022
From
ABIVAX
Via
AccessWire
Abivax Publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'
April 28, 2022
From
ABIVAX
Via
AccessWire
Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis
April 06, 2022
From
ABIVAX
Via
AccessWire
Abivax Reports 2021 Financial Results and Operations Update
March 16, 2022
From
ABIVAX
Via
AccessWire
Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis
March 10, 2022
From
ABIVAX
Via
AccessWire
Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
February 08, 2022
From
ABIVAX
Via
AccessWire
Abivax 2022 Financial Communication Calendar
January 25, 2022
From
ABIVAX
Via
AccessWire
Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer to be Presented on Jan. 21, at ASCO GI Cancers Symposium 2022
January 19, 2022
From
ABIVAX
Via
AccessWire
Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis
January 13, 2022
From
ABIVAX
Via
AccessWire
Exposures
Product Safety
Abivax to Present at the J.P. Morgan 40th Annual Healthcare Conference
December 15, 2021
From
ABIVAX
Via
AccessWire
Exposures
Product Safety
Abivax Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis
December 01, 2021
From
ABIVAX
Via
AccessWire
Exposures
Product Safety
Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer Show Good Tolerability and Promising Signals of Clinical Benefit and were Selected for Presentation at the ASCO GI Cancers Symposium 2022
November 30, 2021
From
ABIVAX
Via
AccessWire
ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis
October 18, 2021
From
ABIVAX
Via
AccessWire
Exposures
Product Safety
Abivax Late-Breaking Abstract Presentation and Live Industry Symposium at the UEG Week Virtual 2021
September 28, 2021
From
ABIVAX
Via
AccessWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.